News on Medial

Trishul Space raises Rs 4 Cr in pre-seed round led by IAN Angel Fund

EntrackrEntrackr · 4d ago
Trishul Space raises Rs 4 Cr in pre-seed round led by IAN Angel Fund
Medial

Rocket propulsion startup Trishul Space has raised Rs 4 crore ($480K) in a pre-seed funding round led by IAN Angel Fund, with participation from 8X Ventures and ITEL. The proceeds will support research, development, and testing of turbopump technology for Harpy-1, the company’s liquid rocket engine designed for small satellite launch vehicles. Founded by Aditya Singh, Divyam, and Rajat Choudhary, Trishul Space builds liquid rocket engines using staged combustion cycles and AI-based failure detection. The company wants to reduce the time, cost, and complexity of building propulsion systems, offering ready-to-use engines for both private and government launch vehicle manufacturers. Trishul Space is addressing a key bottleneck in the space industry where propulsion development is slow, expensive, and resource-heavy. Its goal is to provide modular propulsion systems that enable new launch companies to build faster without starting from scratch. The firm is headquartered in Prayagraj, Uttar Pradesh, and operates from IIT Delhi’s R&I Park, serving government and private launch vehicle manufacturers. Trishul Space is targeting the global market for small and medium launch vehicles, projected to exceed $15 billion by 2030, where propulsion systems contribute 30–40% of launch costs.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 4m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.